Reviva Pharmaceuticals (RVPH) Enters $50M ATM Offering

On May 30, 2025, Reviva Pharmaceuticals (NASDAQ: RVPH) entered into an At Market Issuance Sales Agreement (the “Agreement”) with B. Riley Securities, Inc. and Alliance Global Partners, serving as agents (the “Agents”), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50 million (the “Shares”) through the Agents (the “Offering”). Any Shares offered and sold in the Offering will be issued pursuant to the Company’s shelf Registration Statement on Form S-3 (File No. 333-276848) filed with the Securities and Exchange Commission (the “SEC”) on February 2, 2024, which was declared effective on February 13, 2024, the related prospectus contained therein, and the prospectus supplement relating to the Offering to be filed with the SEC on May 30, 2025 and any applicable additional prospectus supplements related to the Offering that form a part of the Registration Statement.

The Agents may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market (“Nasdaq”) or on any other existing trading market for the Common Stock. The Agents will use commercially reasonable efforts to sell the Shares from time to time consistent with their normal trading and sales practices and applicable state and federal rules, regulations and Nasdaq rules, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Agents a commission equal to three percent (3%) of the gross sales proceeds of any Shares sold through the Agents under the Agreement, and also has provided the Agents with customary indemnification and contribution rights.

The Agents are not required to sell any specific number or dollar amount of the Shares, but will use commercially reasonable efforts to sell, on behalf of the Company, all of the Shares requested to be sold by the Company, consistent with their normal trading and sales practices, on mutually agreed terms between the Agents and the Company. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

You May Also Be Interested In

• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Standard Nuclear names former DOE nuclear policy chief to its board
• KKR to sell 5 million BridgeBio shares in secondary offering